STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.
Hello from STAT's London office, where Andrew Joseph takes the helm for Pharmalot. It's a Wednesday, and we're diving into today's headlines. The White House's recent drug pricing agreements with companies may not have an immediate impact, as they mainly cover Medicaid, which already receives the lowest prices. The deals also exempt companies from mandatory Medicare price reductions.
UniQure submitted its experimental Huntington's gene therapy to the FDA for an accelerated approval review, despite initial rejections based on a Phase 1/2 trial. The FDA later reversed its decision in June, and UniQure has also applied for approval in the U.K. For more details, check out STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy biopharmadive.com
